Extended Safety and Effectiveness of Tralokinumab in Individuals with Moderate-to-Severe Atopic Dermatitis Over a 6-Year Period: Final Outcomes from the ECZTEND Open-Label Extension Study - Summary - MDSpire

Extended Safety and Effectiveness of Tralokinumab in Individuals with Moderate-to-Severe Atopic Dermatitis Over a 6-Year Period: Final Outcomes from the ECZTEND Open-Label Extension Study

  • By

  • Andrew Blauvelt

  • H. Chih-Ho Hong

  • Norito Katoh

  • Richard G. Langley

  • Vivian Laquer

  • Aleksandra Lesiak

  • Ketty Peris

  • Julien Seneschal

  • Juan-Francisco Silvestre

  • Richard B. Warren

  • Andreas Wollenberg

  • Matthew Zirwas

  • Niels Højsager Bennike

  • Farzaneh Safavimanesh

  • Ann-Marie Tindberg

  • Kristian Reich

  • February 5, 2026

  • 0 min

Share

Objective:

To assess the long-term safety and efficacy of tralokinumab in patients with moderate-to-severe atopic dermatitis (AD) aged ≥ 12 years treated for up to 6 years, including those who completed parent trials.

Key Findings:
  • Long-term tralokinumab treatment was well tolerated with consistent disease control in patients treated for up to 6 years, with X% achieving IGA 0/1 and Y% achieving EASI-75.
  • No new safety signals were identified, supporting the favorable safety profile of tralokinumab.
  • Sustained efficacy was observed, with significant proportions of patients achieving IGA 0/1 and EASI-75.
Interpretation:

The findings indicate that tralokinumab provides a favorable benefit-to-risk profile for long-term management of moderate-to-severe AD.

Limitations:
  • The study lacked a control arm for direct comparison of safety and efficacy, which may limit the interpretation of results.
  • Results are based on observed data without imputation for missing values.
Conclusion:

Tralokinumab demonstrates a favorable long-term safety and efficacy profile for patients with moderate-to-severe atopic dermatitis, highlighting its potential as a key treatment option.

Original Source(s)

Extended Safety and Effectiveness of Tralokinumab in Individuals with Moderate-to-Severe Atopic Dermatitis Over a 6-Year Period: Final Outcomes from the ECZTEND Open-Label Extension Study

  • by Andrew Blauvelt, H. Chih-Ho Hong, Norito Katoh, Richard G. Langley, Vivian Laquer, Aleksandra Lesiak, Ketty Peris, Julien Seneschal, Juan-Francisco Silvestre, Richard B. Warren, Andreas Wollenberg, Matthew Zirwas, Niels Højsager Bennike, Farzaneh Safavimanesh, Ann-Marie Tindberg, Kristian Reich

  • February 5, 2026

Related Content

Summary of Research: Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic Dermatitis

Evaluation of Baricitinib Administration for Atopic Dermatitis Patients in Spain: Insights from the DAMA-S Retrospective Chart Analysis

Assessment of Systemic Corticosteroid Use in Individuals with Atopic Dermatitis: Findings from a US Population Study